Pharma industry giants have made giant cuts to their workforces over the past several years--about 143,500 jobs were cut by the world's top 11 drugmakers, FirstWord Pharma reports, citing Bloomberg data.
GlaxoSmithKline ($GSK) has been laying off workers by the hundred over the past several years, just like its Big Pharma rivals. The British press hasn't let national pride get in the way of thumping the U.K.-based company for those job cuts, either.
Merck KGaA management won't use mass firings to reduce its 11,000-employee workforce in Germany to cut costs, Die Welt said, citing a company document.
Targacept has endured a lot lately with the failure of the last two of four Phase III studies of a depression compound on which it was partnered with AstraZeneca ($AZN).
Feeling the sting of the FDA's rejection of its vaginal gel to reduce the risk of preterm birth, Columbia Laboratories ($CBRX) has announced a 42% workforce reduction from 24 to 14 employees.
GlaxoSmithKline ($GSK) employees in the Philadelphia area face big changes in the way they work as the company prepares to relocate to a new building in the Navy Yard. But those changes are only part
Big Pharma employees are worried. According to a new survey from PharmaIQ, some 44% of pharma staffers are anxious they'll lose their jobs. That's probably a sane response, given that drugmakers have
AstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate
The analyst talk was almost half right. AstraZeneca ($AZN) is sharpening its jobs ax for a new round of layoffs. But the number of jobs to be cut isn't 3,000. It's 7,300. Half of the cuts will hit
Abbott Laboratories ($ABT) is laying off about 700 workers as part of its ongoing restructuring, the company says, with "several hundred" more facing the ax by year's end. The news comes almost a